## Peter Francis Rebeiro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8115549/publications.pdf

Version: 2024-02-01

134 papers 3,600 citations

30 h-index 54 g-index

138 all docs

138 docs citations

138 times ranked

4748 citing authors

#	Article	IF	CITATIONS
1	Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor–Based Regimens. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 527-531.	0.9	222
2	Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy. Clinical Infectious Diseases, 2020, 70, 1267-1274.	2.9	218
3	Weight gain among treatmentâ€naà ve persons with HIV starting integrase inhibitors compared to nonâ€nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. Journal of the International AIDS Society, 2020, 23, e25484.	1.2	148
4	End-Stage Renal Disease Among HIV-Infected Adults in North America. Clinical Infectious Diseases, 2015, 60, 941-949.	2.9	142
5	Retention Among North American HIV-Infected Persons in Clinical Care, 2000–2008. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 356-362.	0.9	131
6	Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States. Clinical Infectious Diseases, 2018, 66, 1230-1238.	2.9	131
7	U.S. Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Loads, and CD4 T-Lymphocyte Cell Counts Among HIV-Infected Persons, 2000 to 2008. Annals of Internal Medicine, 2012, 157, 325.	2.0	106
8	Oxidant Stress Is Increased during Treatment of Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 2003, 37, 1711-1717.	2.9	105
9	Race and Sex Differences in Antiretroviral Therapy Use and Mortality among HIVâ€Infected Persons in Care. Journal of Infectious Diseases, 2009, 199, 991-998.	1.9	101
10	Drug Transporter and Metabolizing Enzyme Gene Variants and Nonnucleoside Reverse-Transcriptase Inhibitor Hepatotoxicity. Clinical Infectious Diseases, 2006, 43, 779-782.	2.9	91
11	Trends and Disparities in Antiretroviral Therapy Initiation and Virologic Suppression Among Newly Treatment-Eligible HIV-Infected Individuals in North America, 2001–2009. Clinical Infectious Diseases, 2013, 56, 1174-1182.	2.9	90
12	Impact of Age on Retention in Care and Viral Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 413-419.	0.9	89
13	Pregnancy and HIV Disease Progression during the Era of Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2007, 196, 1044-1052.	1.9	71
14	Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America. Clinical Infectious Diseases, 2017, 65, 636-643.	2.9	67
15	Disparities in the Quality of HIV Care When Using US Department of Health and Human Services Indicators. Clinical Infectious Diseases, 2014, 58, 1185-1189.	2.9	65
16	Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor–Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada. Clinical Infectious Diseases, 2021, 73, e2234-e2242.	2.9	59
17	Changes in rapid HIV treatment initiation after national "treat all―policy adoption in 6 sub-Saharan African countries: Regression discontinuity analysis. PLoS Medicine, 2019, 16, e1002822.	3.9	53
18	CD4 Lymphocyte Percentage Predicts Disease Progression in HIVâ€Infected Patients Initiating Highly Active Antiretroviral Therapy with CD4 Lymphocyte Counts > 350 Lymphocytes/mm3. Journal of Infectious Diseases, 2005, 192, 950-957.	1.9	52

#	Article	IF	CITATIONS
19	Sex, Race, and HIV Risk Disparities in Discontinuity of HIV Care After Antiretroviral Therapy Initiation in the United States and Canada. AIDS Patient Care and STDs, 2017, 31, 129-144.	1.1	50
20	Non-AIDS-defining events among HIV-1-infected adults receiving combination antiretroviral therapy in resource-replete versus resource-limited urban setting. Aids, 2011, 25, 1471-1479.	1.0	47
21	Geographic Variations in Retention in Care among HIV-Infected Adults in the United States. PLoS ONE, 2016, 11, e0146119.	1.1	47
22	Brief Report: Assessing and Interpreting the Association Between Continuous Covariates and Outcomes in Observational Studies of HIV Using Splines. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, e60-e63.	0.9	46
23	Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study. Lancet HIV,the, 2019, 6, e240-e249.	2.1	46
24	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. Clinical Infectious Diseases, 2017, 65, 1316-1326.	2.9	44
25	Drug Use and Receipt of Highly Active Antiretroviral Therapy among HIV-Infected Persons in Two U.S. Clinic Cohorts. PLoS ONE, 2011, 6, e18462.	1.1	43
26	Hepatitis C Viremia and the Risk of Chronic Kidney Disease in HIV-Infected Individuals. Journal of Infectious Diseases, 2013, 208, 1240-1249.	1.9	43
27	First occurrence of diabetes, chronic kidney disease, and hypertension among North American HIV-infected adults, 2000-2013. Clinical Infectious Diseases, 2017, 64, ciw804.	2.9	37
28	Systematic review of prediction models for pulmonary tuberculosis treatment outcomes in adults. BMJ Open, 2021, 11, e044687.	0.8	36
29	Increased vitamin D receptor expression from macrophages after stimulation with M. tuberculosis among persons who have recovered from extrapulmonary tuberculosis. BMC Infectious Diseases, 2019, 19, 366.	1.3	35
30	Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model. American Journal of Epidemiology, 2019, 188, 2097-2109.	1.6	32
31	Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor–Containing Regimens. Clinical Infectious Diseases, 2021, 73, e2153-e2163.	2.9	32
32	Estimated life expectancy gains with antiretroviral therapy among adults with HIV in Latin America and the Caribbean: a multisite retrospective cohort study. Lancet HIV, the, 2021, 8, e266-e273.	2.1	32
33	Postpartum Discontinuation of Antiretroviral Therapy and Risk of Maternal AIDS-Defining Events, Non-AIDS–Defining Events, and Mortality Among a Cohort of HIV-1–Infected Women in the United States. AIDS Patient Care and STDs, 2010, 24, 279-286.	1.1	31
34	Higher Time-Updated Body Mass Index: Association With Improved CD4+ Cell Recovery on HIV Treatment. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 197-204.	0.9	31
35	Mortality Among Persons Entering HIV Care Compared With the General U.S. Population. Annals of Internal Medicine, 2021, 174, 1197-1206.	2.0	31
36	Increased Detectability of Plasma HIVâ€1 RNA after Introduction of a New Assay and Altered Specimenâ€Processing Procedures. Clinical Infectious Diseases, 2008, 47, 1354-1357.	2.9	28

#	Article	IF	Citations
37	Substance Use and Adherence Among People Living with HIV/AIDS Receiving cART in Latin America. AIDS and Behavior, 2016, 20, 2692-2699.	1.4	28
38	Daily Marijuana Use is Associated with Missed Clinic Appointments Among HIV-Infected Persons Engaged in HIV Care. AIDS and Behavior, 2017, 21, 1996-2004.	1.4	28
39	Strong Agreement of Nationally Recommended Retention Measures from the Institute of Medicine and Department of Health and Human Services. PLoS ONE, 2014, 9, e111772.	1.1	27
40	The relationship between adverse neighborhood socioeconomic context and HIV continuum of care outcomes in a diverse HIV clinic cohort in the Southern United States. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 1426-1434.	0.6	27
41	HIV-1 Transmission Clustering and Phylodynamics Highlight the Important Role of Young Men Who Have Sex with Men. AIDS Research and Human Retroviruses, 2018, 34, 879-888.	0.5	27
42	Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada. Clinical Infectious Diseases, 2020, 70, 1176-1185.	2.9	27
43	Health Literacy and Demographic Disparities in HIV Care Continuum Outcomes. AIDS and Behavior, 2018, 22, 2604-2614.	1.4	26
44	Characterizing the Human Immunodeficiency Virus Care Continuum Among Transgender Women and Cisgender Women and Men in Clinical Care: A Retrospective Time-series Analysis. Clinical Infectious Diseases, 2020, 70, 1131-1138.	2.9	26
45	Impact of Culture-Independent Diagnostic Testing on Recovery of Enteric Bacterial Infections. Clinical Infectious Diseases, 2018, 66, 1892-1898.	2.9	25
46	Diagnosis and clinical outcomes of extrapulmonary tuberculosis in antiretroviral therapy programmes in low―and middle―income countries: a multicohort study. Journal of the International AIDS Society, 2019, 22, e25392.	1.2	24
47	Laboratory Measures as Proxies for Primary Care Encounters: Implications for Quantifying Clinical Retention Among HIV-Infected Adults in North America. American Journal of Epidemiology, 2015, 182, 952-960.	1.6	22
48	Tennessee's In-state Vulnerability Assessment for a "Rapid Dissemination of Human Immunodeficiency Virus or Hepatitis C Virus Infection―Event Utilizing Data About the Opioid Epidemic. Clinical Infectious Diseases, 2018, 66, 1722-1732.	2.9	22
49	Human Immunodeficiency Virus (HIV) Viral Suppression After Transition From Having No Healthcare Coverage and Relying on Ryan White HIV/AIDS Program Support to Medicaid or Private Health Insurance. Clinical Infectious Diseases, 2019, 69, 538-541.	2.9	21
50	Race, Kidney Disease Progression, and Mortality Risk in HIV-Infected Persons. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2269-2275.	2.2	20
51	A Flow-Based Model of the HIV Care Continuum in the United States. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 548-553.	0.9	20
52	A Pragmatic Approach for Reproducible Research With Sensitive Data. American Journal of Epidemiology, 2017, 186, 387-392.	1.6	20
53	The shifting age distribution of people with HIV using antiretroviral therapy in the United States. Aids, 2022, 36, 459-471.	1.0	20
54	The Impact of COVID-19 on the HIV Care Continuum in a Large Urban Southern Clinic. AIDS and Behavior, 2022, 26, 2825-2829.	1.4	20

#	Article	IF	Citations
55	Implications of T-Cell P-Glycoprotein Activity During HIV-1 Infection and Its Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 119-126.	0.9	19
56	The Population Impact of Late Presentation With Advanced HIV Disease and Delayed Antiretroviral Therapy in Adults Receiving HIV Care in Latin America. American Journal of Epidemiology, 2020, 189, 564-572.	1.6	19
57	The relationship between injection and noninjection drug use and HIV disease progression. Journal of Substance Abuse Treatment, 2011, 41, 14-20.	1.5	17
58	Use of Social Network Strategy Among Young Black Men Who Have Sex With Men for HIV Testing, Linkage to Care, and Reengagement in Care, Tennessee, 2013-2016. Public Health Reports, 2018, 133, 43S-51S.	1.3	17
59	Global variations in mortality in adults after initiating antiretroviral treatment. Aids, 2019, 33, S283-S294.	1.0	16
60	Antiretroviral Therapy Initiation Before, During, or After Pregnancy in HIV-1-Infected Women: Maternal Virologic, Immunologic, and Clinical Response. PLoS ONE, 2009, 4, e6961.	1,1	15
61	leDEA-WHO Research-Policy Collaboration: contributing real-world evidence to HIV progress reporting and guideline development. Journal of Virus Eradication, 2018, 4, 9-15.	0.3	15
62	Estimating the Optimal CD4 Count for HIV-infected Persons to Start Antiretroviral Therapy. Epidemiology, 2010, 21, 698-705.	1.2	14
63	Risk Prediction Tool for Medical Appointment Attendance Among HIV-Infected Persons with Unsuppressed Viremia. AIDS Patient Care and STDs, 2015, 29, 240-247.	1.1	14
64	Assessing the HIV Care Continuum in Latin America: progress in clinical retention, cART use and viral suppression. Journal of the International AIDS Society, 2016, 19, 20636.	1.2	14
65	The Impact of State Mask-Wearing Requirements on the Growth of Coronavirus Disease 2019 Cases, Hospitalizations, and Deaths in the United States. Clinical Infectious Diseases, 2021, 73, 1703-1706.	2.9	14
66	Tuberculosis Risk Before and After Highly Active Antiretroviral Therapy Initiation: Does HAART Increase the Short-Term TB Risk in a Low Incidence TB Setting?. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 305-310.	0.9	13
67	One Size Fits (n)One: The Influence of Sex, Age, and Sexual Human Immunodeficiency Virus (HIV) Acquisition Risk on Racial/Ethnic Disparities in the HIV Care Continuum in the United States. Clinical Infectious Diseases, 2019, 68, 795-802.	2.9	13
68	Trends in HIV Continuum of Care Outcomes over Ten Years of Follow-Up at a Large HIV Primary Medical Home in the Southeastern United States. AIDS Research and Human Retroviruses, 2017, 33, 1027-1034.	0.5	12
69	Evaluating the care cascade after antiretroviral therapy initiation in Latin America. International Journal of STD and AIDS, 2018, 29, 4-12.	0.5	12
70	Hospitalization Rates and Causes Among Persons With HIV in the United States and Canada, 2005–2015. Journal of Infectious Diseases, 2021, 223, 2113-2123.	1.9	12
71	Tennessee Healthcare Provider Practices, Attitudes, and Knowledge Around HIV Pre-Exposure Prophylaxis. Journal of Primary Care and Community Health, 2020, 11, 215013272098441.	1.0	12
72	Hemoglobin May Contribute to Sex Differences in Mortality among HIV-Infected Persons in Care. PLoS ONE, 2012, 7, e44999.	1.1	11

#	Article	IF	CITATIONS
73	The 2013 HIV Continuum of Care in Tennessee. Public Health Reports, 2016, 131, 695-703.	1.3	11
74	Observational Study of the Effect of Patient Outreach on Return to Care: The Earlier the Better. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 141-148.	0.9	11
75	Temporal Trends and Sociodemographic Correlates of PrEP Uptake in Tennessee, 2017. AIDS and Behavior, 2019, 23, 304-312.	1.4	11
76	The impact of data quality and source data verification on epidemiologic inference: a practical application using HIV observational data. BMC Public Health, 2019, 19, 1748.	1.2	11
77	Is substance use associated with HIV cascade outcomes in Latin America?. PLoS ONE, 2018, 13, e0194228.	1.1	11
78	Mood Disorders and Increased Risk of Noncommunicable Disease in Adults With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 397-404.	0.9	10
79	Implications of COVIDâ€19 for HIV Research: data sources, indicators and longitudinal analyses. Journal of the International AIDS Society, 2020, 23, e25627.	1.2	10
80	Five-Year Mortality for Adults Entering Human Immunodeficiency Virus Care Under Universal Early Treatment Compared With the General US Population. Clinical Infectious Diseases, 2022, 75, 867-874.	2.9	10
81	A Clinical Prediction Model for Unsuccessful Pulmonary Tuberculosis Treatment Outcomes. Clinical Infectious Diseases, 2022, 74, 973-982.	2.9	9
82	CD4 Response Up to 5 Years After Combination Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Patients in Latin America and the Caribbean. Open Forum Infectious Diseases, 2015, 2, ofv079.	0.4	8
83	A picture is worth a thousand words: maps of HIV indicators to inform research, programs, and policy from NAâ€ACCORD and CCASAnet clinical cohorts. Journal of the International AIDS Society, 2016, 19, 20707.	1.2	8
84	Health outcomes among HIVâ€positive Latinos initiating antiretroviral therapy in North America versus Central and South America. Journal of the International AIDS Society, 2016, 19, 20684.	1.2	8
85	Clinical and Virologic Outcomes After Changes in First Antiretroviral Regimen at 7 Sites in the Caribbean, Central and South America Network. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 102-110.	0.9	8
86	New Faces of HIV Infection: Age, Race, and Timing of Entry into HIV Care in the Southeastern United States. Journal of the International Association of Providers of AIDS Care, 2017, 16, 347-352.	0.6	8
87	Estimating a Set of Mortality Risk Functions with Multiple Contributing Causes of Death. Epidemiology, 2020, 31, 704-712.	1.2	8
88	Knowledge and stigma of latent tuberculosis infection in Brazil: implications for tuberculosis prevention strategies. BMC Public Health, 2020, 20, 897.	1.2	8
89	CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018. Clinical Infectious Diseases, 2021, 73, e2334-e2337.	2.9	8
90	Projecting the age-distribution of men who have sex with men receiving HIV treatment in the United States. Annals of Epidemiology, 2022, 65, 46-55.	0.9	8

#	Article	IF	CITATIONS
91	Viral suppression among persons in HIV care in the United States during 2009–2013: sampling bias in Medical Monitoring Project surveillance estimates. Annals of Epidemiology, 2019, 31, 3-7.	0.9	7
92	Interactive Data Visualization for HIV Cohorts: Leveraging Data Exchange Standards to Share and Reuse Research Tools. PLoS ONE, 2016, 11, e0151201.	1.1	6
93	Medically Attended Catheter Complications Are Common in Patients With Outpatient Central Venous Catheters. Infection Control and Hospital Epidemiology, 2018, 39, 439-444.	1.0	6
94	Lack of Weight Gain During the First 2 Months of Treatment and Human Immunodeficiency Virus Independently Predict Unsuccessful Treatment Outcomes in Tuberculosis. Journal of Infectious Diseases, 2020, 221, 1416-1424.	1.9	6
95	Clinical Effectiveness of Integrase Strand Transfer Inhibitor–Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada. Clinical Infectious Diseases, 2020, 73, e1408-e1414.	2.9	6
96	Resistance-Conferring Mutations on Whole-Genome Sequencing of Fluoroquinolone-resistant and -Susceptible Mycobacterium tuberculosis Isolates: A Proposed Threshold for Identifying Resistance. Clinical Infectious Diseases, 2021, 72, 1910-1918.	2.9	6
97	Clinic-Level Factors Associated With Retention in Care Among People Living With Human Immunodeficiency Virus in a Multisite US Cohort, 2010–2016. Clinical Infectious Diseases, 2020, 71, 2592-2598.	2.9	5
98	Development and Validation of a Multivariable Prediction Model for Missed HIV Health Care Provider Visits in a Large US Clinical Cohort. Open Forum Infectious Diseases, 2021, 8, ofab130.	0.4	5
99	Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy. Aids, 2022, 36, 277-286.	1.0	5
100	Individual, community, and structural factors associated with linkage to HIV care among people diagnosed with HIV in Tennessee. PLoS ONE, 2022, 17, e0264508.	1.1	5
101	Early Retention in Care Neither Mediates Nor Modifies the Effect of Sex and Sexual Mode of HIV Acquisition on HIV Survival in the Americas. AIDS Patient Care and STDs, 2018, 32, 306-313.	1.1	4
102	Temporal changes in ART initiation in adults with high CD4 counts in Latin America: a cohort study. Journal of the International AIDS Society, 2019, 22, e25413.	1.2	4
103	Virologic, Immunologic and Clinical Responses in Foreign-Born versus US-Born HIV-1 Infected Adults Initiating Antiretroviral Therapy: An Observational Cohort Study. PLoS ONE, 2012, 7, e52336.	1.1	4
104	475. Describing the impact of the COVID-19 pandemic on HIV care in Latin America. Open Forum Infectious Diseases, 2020, 7, S303-S304.	0.4	4
105	Improving HIV Surveillance Among Transgender Populations in Tennessee. LGBT Health, 2016, 3, 208-213.	1.8	3
106	Substance Use, Demographic and Socioeconomic Factors Are Independently Associated With Postpartum HIV Care Engagement in the Southern United States, 1999–2016. Open Forum Infectious Diseases, 2019, 6, ofz023.	0.4	3
107	Current and Past Immunodeficiency Are Associated With Higher Hospitalization Rates Among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years. Journal of Infectious Diseases, 2021, 224, 657-666.	1.9	3
108	Chronic kidney disease at presentation is not an independent risk factor for AIDS-defining events or death in HIV-infected persons. Clinical Nephrology, 2013, 79, 93-100.	0.4	3

#	Article	IF	CITATIONS
109	Misdiagnosis of HIV infection: implications for universal testing. Aids, 2008, 22, 546-547.	1.0	2
110	Trends and Disparities in Mortality and Progression to AIDS in the Highly Active Antiretroviral Therapy Era: Tennessee, 1996–2016. American Journal of Public Health, 2019, 109, 1266-1272.	1.5	2
111	Methodologic Considerations for Small Cohort Studies. Clinical Infectious Diseases, 2019, 69, 1644-1644.	2.9	2
112	Risk of HIV Diagnosis Following Bacterial Sexually Transmitted Infections in Tennessee, 2013–2017. Sexually Transmitted Diseases, 2021, 48, 873-880.	0.8	2
113	Who Is Not Linking to HIV Care in Tennessee — the Benefits of an Intersectional Approach. Journal of Racial and Ethnic Health Disparities, 2022, 9, 849-855.	1.8	2
114	Timing of HIV diagnosis relative to pregnancy and postpartum HIV care continuum outcomes among Latin American women, 2000 to 2017. Journal of the International AIDS Society, 2021, 24, e25740.	1.2	2
115	Achieving consistency in measures of HIVâ€1 viral suppression across countries: derivation of an adjustment based on international antiretroviral treatment cohort data. Journal of the International AIDS Society, 2021, 24, e25776.	1.2	2
116	Weight gain post-ART in HIV+ Latinos/as differs in the USA, Haiti, and Latin America. The Lancet Regional Health Americas, 2022, 8, 100173.	1.5	2
117	Exploring definitions of retention in care for people living with HIV in the United States in the modern treatment era. Aids, 2022, 36, 1181-1189.	1.0	2
118	Possible sex difference in latent tuberculosis infection risk among close tuberculosis contacts. International Journal of Infectious Diseases, 2022, 122, 685-692.	1.5	2
119	Reply to Amendola et al Clinical Infectious Diseases, 2009, 48, 1631-1632.	2.9	1
120	Weight Gain After Switch from Efavirenz-Based to Integrase Inhibitor-Based Regimens. Open Forum Infectious Diseases, 2017, 4, S433-S433.	0.4	1
121	Association Between Patient Portal Access and Viral Suppression Among People Living with HIV in a Large Southeastern Clinical Cohort. Open Forum Infectious Diseases, 2017, 4, S40-S40.	0.4	1
122	RE: Role of rapid diagnostics for viral respiratory infections in antibiotic prescribing decision in the emergency department, by Li et al (2019). Infection Control and Hospital Epidemiology, 2020, 41, 991-992.	1.0	1
123	The HIV care cascade in Buenos Aires, Argentina: results in a tertiary referral hospital. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2016, 40, 448-454.	0.6	1
124	Visualizing the geography of HIV observational cohorts with density-adjusted cartograms. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, Publish Ahead of Print, .	0.9	1
125	Racial and Ethnic Disparities in Hospital Readmissions After Delivery. Obstetrics and Gynecology, 2016, 127, 799.	1.2	0
126	Letter to the Editor. Tuberculosis, 2018, 113, 122-124.	0.8	0

#	Article	IF	CITATIONS
127	3309 Clinic-Level Factors and Retention in Care among People Living with HIV (PLWH) in a United States (US) Multi-Site Cohort, 2010-2016. Journal of Clinical and Translational Science, 2019, 3, 85-86.	0.3	O
128	3166 Association between HIV and early weight loss and the impact on subsequent treatment outcomes among patients with tuberculosis. Journal of Clinical and Translational Science, 2019, 3, 34-34.	0.3	0
129	1286. Healthcare Provider Attitudes and Knowledge Around Pre-Exposure Prophylaxis (PrEP) for the Prevention of HIV-Infection in Tennessee. Open Forum Infectious Diseases, 2019, 6, S463-S463.	0.4	0
130	Outcomes After Second-Line Antiretroviral Therapy in Children Living with HIV in Latin America. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, Publish Ahead of Print, 993-1001.	0.9	0
131	1421. Assessing Serious Infections Common in Persons Who Inject Drugs in the United States and Tennessee. Open Forum Infectious Diseases, 2020, 7, S717-S718.	0.4	0
132	53. Sex and Race Disparities in Premature Mortality among People with HIV: A 21-Year Observational Cohort Study. Open Forum Infectious Diseases, 2021, 8, S37-S37.	0.4	0
133	Clinical effects of durability of immunosuppression in virologically suppressed ART-initiating persons with HIV in Latin America. A retrospective cohort study. The Lancet Regional Health Americas, 2022, 8, 100175.	1.5	O
134	51. Patient Reported Outcomes Collection: A Mixed Methods Study at an urban HIV Clinic associated with a Historically Black Medical College in the Southern United States. Open Forum Infectious Diseases, 2021, 8, S35-S36.	0.4	0